RxDoctor Payments Data

Lindsay Kilburn

Pediatric Hematology-Oncology · Houston, TXNPI 1023215944

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $3,950 of the $4,053 with a category attached, or 97.5%. 3 manufacturers reported payments, led by F. Hoffmann-la Roche AG at 51.0% of the total.

$4,053in general payments, 2019–2025

Across 4 payments — averaging $1013.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • F. Hoffmann-la Roche AG$2K
  • Jazz Pharmaceuticals Inc.$2K
  • Janssen Research & Development, LLC$35
$1,447,440in research payments, 2019–2025

Across 128 payments — averaging $11,308 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$826K
  • Regeneron$310K
  • Day One Biopharmaceuticals$139K
  • Epizyme, Inc.$87K
  • Springworks Therapeutics, Inc.$66K
  • Eli Lilly$18K
  • plus $611 from 1 others

What the payments were for

  • Consulting fees$3,95097%
  • Food & beverage$1033%

General payments by program year

19
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,053 in reported general payments places this provider in the 75th percentile of 235 pediatric hematology-oncology providers in Texas.

See all pediatric hematology-oncology providers in Texas

Other pediatric hematology-oncology in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →